A start towards immunotherapy in sarcomas?
Mené aux Etats-Unis sur 85 patients atteints d'un sarcome de stade localement avancé, non résécable ou de stade métastatique, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité du nivolumab, utilisé en monothérapie ou en combinaison avec l'ipilimumab
Few data are available on the immunological aspects of soft tissue and bone sarcomas compared with other types of cancer, such as malignant melanoma. In 2013, Rusakiewicz and colleagues1 investigated the immune infiltrates of gastrointestinal stromal tumours and found that CD3-positive tumour-infiltrating lymphocytes were highly activated and particularly present in areas of tumour tissue that conserved class I major histocompatibility complex (MHC) expression despite imatinib therapy. Subsequently, Tawbi and colleagues2 treated 86 patients who had advanced bone and soft tissue sarcomas with pembrolizumab in a phase 2 study and observed nine responses in 80 evaluable patients.
The Lancet Oncology 2018